Major Breakthrough in Type 1 Diabetes Treatment
Teplizumab, the first drug globally designed to postpone the onset of type 1 diabetes, will now be accessible through the NHS in England and Wales. This development is being hailed as the most substantial progress in combating the disease in over a century.
Understanding Type 1 Diabetes
Type 1 diabetes affects millions worldwide and typically manifests during childhood or adolescence. It is characterized by the pancreas's inability to produce sufficient or any insulin. Insulin is a vital hormone that facilitates the entry of glucose into cells, where it is converted into energy.
Impact of Teplizumab
The availability of teplizumab on the NHS is described as an 'incredible moment' for patients and healthcare professionals. Clinical trials have demonstrated its capacity to delay the progression of the early stages of type 1 diabetes for as long as three years, offering a crucial window for individuals at risk.
Source: Original Article